Isofol Medical AB (publ)

Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option

Mon, Jun 14, 2021 10:00 CET

GOTHENBURG, Sweden, June 14, 2021 - Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the “Company”) fully guaranteed new share issue with preferential rights for the Company’s existing shareholders (the “Rights Issue”), which ended on June 10, 2021, was oversubscribed. Due to the strong demand from strategic investors, a directed issue with deviation from the shareholders’ preferential rights of approximately SEK 100 million (the “Over-Allotment Option”) was exercised. Through the Rights Issue and the Over-Allotment Option, Isofol will receive proceeds

Consortium of investors acquires subscription rights from Isofol´s founder Professor Bengt Gustavsson

Fri, May 29, 2020 08:45 CET

GOTHENBURG, Sweden, May 29, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the “Company”), has been informed by Professor Bengt Gustavsson – founder and largest owner of Isofol – that Professor Gustavsson has initiated that all the subscription rights held by Biofol AB (an affiliated company to Professor Gustavsson), obtained in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million, has been purchased by a consortium of investors.The consortium of investors has committed to Professor Gustavsson that

Share

Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option

Consortium of investors acquires subscription rights from Isofol´s founder Professor Bengt Gustavsson

Subscribe